GeNeuro announced on Tuesday the completion of enrolment in its Phase 2 clinical trial in long-onset Covid, with first results expected in June 2024.

The biopharmaceutical company points out that over 200 patients have been randomized in this precision medicine study, making it one of the largest trials in long-onset Covid.

The study aims to assess the efficacy and safety of treatment with its temelimab in terms of improvement in measures of fatigue and cognitive impairment.

Expression of the pathogenic protein W-ENV, suspected of playing a major role in the persistence of inflammation and neurological symptoms, is confirmed in more than a third of selected patients.

Copyright (c) 2023 CercleFinance.com. All rights reserved.